Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Metadata lists "KORU Medical Systems, Inc." but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: November 30, 2010
Business Overview: The Company researches, develops, and markets medical devices, primarily the Freedom60 syringe infusion pump for ambulatory medication and the RES-Q-VAC emergency airway suction system. The Company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Nov 30, 2010 | Nine Months Ended Nov 30, 2010 | Nine Months Ended Nov 30, 2009 |
|---|---|---|---|
| Net Sales | $1,254,198 | $3,316,528 | $2,658,288 |
| Net Income | $168,149 | $357,801 | $230,149 |
| Net Operating Profit | $290,314 | $605,381 | $400,859 |
| Gross Margin | 67.2% | 65.6% | 65.1% |
| Net Cash from Operations | N/A | $792,888 | $132,790 |
| Cash and Equivalents (Nov 30, 2010) | $1,362,903 | ||
| Total Debt (Current + Long-term) | $573,916 |
Note: Total Debt includes $40,324 current portion and $533,592 long-term portion as of Nov 30, 2010.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 39.6% for the quarter and 24.8% for the nine-month period compared to the prior year. This was driven by a 42.5% increase in Freedom60 sales for the quarter and a 38.6% increase for the nine-month period.
- Profitability: Net income surged 203.1% for the quarter and 55.5% for the nine-month period. Net operating profit increased 166.9% for the quarter.
- Expense Management: Selling, General, and Administrative (SG&A) expenses increased 15.3% for the quarter but declined as a percentage of sales from 51.0% to 42.1%. Interest expense decreased 27.6% for the quarter due to debt reduction.
- Cash Flow: Net cash provided by operating activities improved significantly to $792,888 for the nine months ended Nov 30, 2010, compared to $132,790 in the prior year, driven by increased profits and a decrease in accounts receivable.
- Debt Reduction: The Company repaid a $100,000 demand loan to the President in June 2010. Half of the accrued interest was forgiven and recorded as income.
Guidance, Outlook, and Risks
- Outlook: Management expects the Freedom60 market to continue growing domestically and internationally, particularly with the introduction of a new 20% IgG drug solution. The Company believes current capital and cash increases will meet financial needs for the next twelve months.
- Government Grant: The Company received a $150,000 grant from the Trade Adjustment Assistance Program (50-50 match) for marketing and regulatory affairs. Approximately $7,500 remained available as of Nov 30, 2010.
- Risks: Key risks include dependence on key personnel, FDA regulatory changes, reimbursement risks (specifically Medicare HCPCS coding), and competition from electronic infusion devices or new drug formulations (e.g., Hyaluronidase).
- Contingencies: The Company is contingently liable for approximately $10,000 in rework costs for a customer order, which has been provisioned in the financial statements.
Investor Verification Checklist
- Revenue Concentration: Verify the extent of reliance on the Freedom60 product line, which drove the majority of recent sales growth.
- Reimbursement Stability: Confirm the status of Medicare HCPCS code E0779 and any potential changes in reimbursement rates for mechanical infusion pumps.
- Related Party Transactions: Review the terms of the remaining $527,652 loan from a director and the lease agreement for the aircraft controlled by the President.
- Inventory Levels: Assess the increase in inventory ($689,332) relative to sales velocity to ensure no obsolescence risk.
- Stock Option Dilution: Note that 2,150,000 stock options are outstanding and exercisable at $0.06 per share, which could impact future earnings per share.